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Erik Mirkov (Texas A&M University, College Station):  Alan, what is your opinion on 
not only the September 5 Monsanto patent but also the one issued December 8? Do 
you see coexistence with the Syngenta patents?
Alan Bennett:  I think I know the Syngenta patents you are talking about—I thought 
they had expired. They originally came from Washington University, I think. I’m not 
sure about coexistence. Sorry.
Roger Beachy (Global Institute for Food Security, Saskatoon):  What chance is there that 
Monsanto will do a “Cohen and Boyer”?
Bennett:  Little, but I think they should be encouraged to.
Beachy: Absolutely.  That’s the point. This is terribly important. It’s an enabler just like 
the “Cohen and Boyer” patent was. That’s what the industry needs. Are we going to play 
in sandboxes or are we going to play in the big field?
Bennett: Yes, the landscape has changed so much. The intellectual property portfolio—key 
patents that Monsanto had—were really important in establishing them in the industry 
in a very strong position. Clearly, those tools are not valuable in the same way today, and 
enabling an entire industry might be to everyone’s advantage, including Monsanto’s.
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Tom Redick (Global Environmental Ethics Council, Clayton):  Scott, a question mostly 
for you. I’m the guy who started major market approval as a big problem for all the sick 
sisters of biotech and we are starting to talk about whether certain closed-loop1 identity-
preserved production models could work for, say, a specialty crop.  I’m wondering, is there a 
way we could carve out a corner of the world where we could grow it in a confined district 
in a confined production system so that we don’t interfere with the markets overseas?
Scott Thenell:  Tom, you are probably right that it can be done with a considerable amount 
of planning, and reassurance for trading partners that it is robust. Also from a regulatory 
approval standpoint, yes, if you can develop a robust identity-preservation closed-loop 
system, then I think you can.
Tim Hall (Texas A&M University, College Station):  It was mentioned that the Monsanto 
Agrobacterium patent was very strong and very solid for dicot crops. Do you think it is 
equally strong for monocots, considering that it has been found to be extremely good 
in rice, for example?
Bennett:  That particular patent is specific for dicots. Other strong monocot patents exist 
as well, but this is not one of them.
Hall:  For monocots? Agrobacterium-mediated? When you say there are other systems, 
other patents, do you mean including Agrobacterium-mediated?
Bennett:  Yes, Agrobacterium-mediated transformation in monocots—strong patents 
exist.
Peter Schuerman: One of the questions we get a lot within the university is about whether 
or not a patent might be a problem. It’s very easy to think about patents as problems 
rather than as opportunities. Universities got into the patent system about 00 years too 
late. We’ve been innovating the whole time, but better late than never. A patent is an 
opportunity for a conversation. A kind of conversation that universities aren’t used to 
having. If what you want to do infringes on someone else’s rights, you can talk to that 
someone else and say, “Here is how it’s beneficial to both of us,” then it is not a problem, 
it’s an opportunity.
Bennett: That’s a good point. Dennis Gonsalves2 has experienced that. When he had a 
product, it was clear what it was, he went to the patent owners: not a problem. But I’m 
going to refer to one of your slides, Peter, where there was uncertainty for the investiga-
tor— uncertainty as to whether something would work out or not. “Should I even start 
down that path?” That’s the other issue with patent portfolios: they cloud the future.
1Closed loop: see pages 3, 5 and 56.
2Pages 37–46.
